April 27, 2015
VIENNA — The presence of hepatitis C virus infection RNA in liver explants did not correlate with a likelihood of hepatitis C recurrence after liver transplantation, according to study results presented at the 2015 International Liver Congress.
“Hepatitis C recurrence is universal in patients with detectable HCV RNA at time of liver transplantation,” Martina Gambato, MD, Liver Unit, University of Barcelona, Spain, said during her presentation. “Due to the high efficacy and good safety profile of direct-acting antivirals, most patients awaiting [liver transplant] will undergo antiviral therapy. Residual HCV RNA in the liver explants has been previously shown to be associated to HCV recurrence in patients treated with [pegylated interferon and ribavirin] on the waiting list.”